A multi-centric, randomized, double blind study to evaluate the safety and efficacy of 2mg and 4mg of ZYH1 compared to Pioglitazone 45mg in dyslipidemia with type 2 diabetes mellitus.

Trial Profile

A multi-centric, randomized, double blind study to evaluate the safety and efficacy of 2mg and 4mg of ZYH1 compared to Pioglitazone 45mg in dyslipidemia with type 2 diabetes mellitus.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs Pioglitazone; Saroglitazar
  • Indications Dyslipidaemias; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms PRESS V
  • Most Recent Events

    • 28 Nov 2012 Planned number of patients changed from 120 to 122 as reported by Clinical Trials Registry - India record.
    • 19 Jul 2012 Actual initiation date changed from 19 Aug 2009 to 27 Jul 2009 as reported by Clinical Trials Registry - India record.
    • 08 Sep 2010 Status changed from active, no longer recruiting to completed as reported by Clinical Trials Registry - India record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top